



Premature termination of a Clinical Trial

Full title of the clinical Trial: Very low doses of Rituximab for off-label treatment – a Pilot Trial

EudraCT Number: 2016-002478-11

Sponsor: Medical University of Vienna

Represented by (name): Jilma, Bernd, Univ.-Prof. Dr.med.univ.

Reason for premature termination

of the clinical trial: Due to COVID-19 pandemic, and a higher risk for severe courses in COVID patients after receiving rituximab, other treatment modalities have taken priority.

Study results (if available):

Date and Signature of Sponsor representative:



Dr. Bernd Aichele